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Background: Early diagnosis and appropriate treatment of infections in cirrhosis are crucial. As 
new guidelines in this context, particularly for health care-associated (HCA) infections, would 
be needed, we performed a trial documenting whether an empirical broad-spectrum antibiotic 
therapy is more effective than the standard one for these infections. Because of the higher daily 
cost of broad-spectrum than standard antibiotics, we performed a cost analysis to compare: 
1) total drug costs, 2) profitability of hospital admissions.
Methods: This retrospective observational analysis was performed on patients enrolled in the 
trial NCT01820026, in which consecutive cirrhotic patients with HCA infections were randomly 
assigned to a standard vs a broad-spectrum treatment. Antibiotic daily doses, days of treatment, 
length of hospital stay, and DRG (diagnosis-related group) were recorded from the clinical trial 
medical records. The profitability of hospitalizations was calculated considering DRG tariffs 
divided by length of hospital stay.
Results: We considered 84 patients (42 for each group). The standard therapy allowed to obtain 
a first-line treatment cost lower than in the broad-spectrum therapy. Anyway, the latter, being 
related to a lower failure rate (19% vs 57.1%), resulted in cost saving in terms of cumulative 
antibiotic costs (first- and second-line treatments). The mean cost saving per patient for the 
broad-spectrum arm was €44.18 (–37.6%), with a total cost saving of about €2,000. Compared 
to standard group, we observed a statistically significant reduction in hospital stay from 17.8 
to 11.8 days (p<0.002) for patients treated with broad-spectrum antibiotics. The distribution of 
DRG tariffs was similar in the two groups. According to DRG, the shorter length of hospital 
stay of the broad-spectrum group involved a higher mean profitable daily cost than standard 
group (€345.61 vs €252.23; +37%).
Conclusion: Our study supports the idea that the use of a broad-spectrum empirical treatment 
for HCA infections in cirrhosis would be cost-saving and that hospitals need to be aware of the 
clinical and economic consequences of a wrong antibiotic treatment in this setting.
Keywords: profitability, diagnosis-related group, cost saving, antibiotic failure
Introduction
Bacterial infections occur in about one-third of hospitalized cirrhotic patients, with an 
incidence 4–5-fold higher than in hospitalized patients with other diseases.1,2
The main types of infections in those patients are spontaneous bacterial perito-
nitis (25%–31%), urinary tract infection (20%–40%), pneumonia (15%–21%), and 
bacteremia (12%).2–4
Bacterial infections in cirrhosis are associated with poor outcomes (mortality is 
higher about 4 times), accounting for about 30%–50% of deaths in cirrhotic patients.5–8 
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The prognosis is particularly severe in the absence of prompt 
adequate therapeutic treatment.9–11 Early diagnosis and 
appropriate empirical treatment of infections in cirrhosis are 
crucial; a delay in starting antibiotic therapy is associated with 
a relevant mortality increasing by the hour.12,13
Since 2000, third-generation cephalosporins have been 
considered the gold standard in the treatment of most infec-
tions in patients with cirrhosis because of their effectiveness 
against Enterobacteriaceae and non-enterococcus streptococ-
cus and also because of their low hepatic and renal toxicity.
However, these recommendations were based on the 
results of trials carried out in the 1980s and 1990s, when 
the epidemiological and microbiological characteristics of 
the infections were very different. In the last decade, in fact, 
gram-positive and multidrug-resistant (MDR) pathogens 
have become more prevalent, particularly in the nosocomial 
setting, as a result of the progressive shift in care from home 
to health care facilities.14–17
In a large prospective study on cirrhotic patients with 
infections, multiresistant bacteria (18%) were isolated in 4% 
of community-acquired (CA) and 35% of hospital-acquired 
(HA) infections.2 In the more recently individuated epide-
miological class, including infections occurring in patients 
who had previous recent contacts with the health care system 
(health care-associated [HCA] infections), a rate of 14% of 
MDR was reported in cirrhotic patients.14–16
As a consequence, the efficacy of empirical antibiotic 
treatment progressively decreased from CA to HCA and 
HA infections.9
From these observations, it can be inferred that the choice 
of an antibiotic treatment needs to be more accurate and 
personalized based on epidemiological class, the presence of 
risk factors for MDR, and the local microbiological pattern.
Recent international guidelines, updated in 2012, and an 
international position statement published in 2013 have sug-
gested new therapeutic approaches to CA and HA infections.12,17
The high rate of antibiotic resistance (14%–50% in dif-
ferent countries) in HCA infections, and their poor prognosis 
has sparked off a debate about the possible advantages or 
disadvantages of using a broad-spectrum antibiotic as a first-
line treatment in these infections.9,12,15,16 No controlled trials 
were available on this matter, and HCA infections are still 
usually treated as CA with a detrimental effect on survival. 
No specific guidelines or indications are available at present 
for HCA infections.
For this reason, in a recent study, for the first time, the 
hypothesis was tested that an empirical broad-spectrum 
 antibiotic treatment would be more effective than the standard 
therapy in the treatment of cirrhotic patients with HCA infec-
tions. A randomized trial (NCT01820026) was performed 
in which 96 consecutive patients with cirrhosis hospitalized 
with HCA infections were randomized to receive a standard 
(48 patients) or a broad-spectrum (48 patients) antibiotic 
treatment.18 In this study, the broad-spectrum therapy was 
associated to a lower rate of failure than the standard therapy 
(18% vs 51%; p<0.001). Compared with standard therapy, 
broad-spectrum therapy showed a substantial reduction in 
the rate of in-hospital mortality and in the length of hospital 
stay. Moreover, in a post hoc analysis, reduction of mortality 
was more evident in patients with sepsis.
Because of the higher daily cost of broad-spectrum antibi-
otics than standard antibiotics, we performed a cost analysis 
in order to evaluate the medical direct costs of the two anti-
biotic treatments. The primary aim of the cost analysis was 
the comparison of total drug costs and length of hospital stay 
upon using a broad-spectrum antibiotic therapy with respect 
to using standard antibiotic therapy. Secondarily, the profit-
ability of hospital admissions (remuneration per inpatient 
day) with patients treated with broad-spectrum or standard 
therapy was estimated.
Methods
Clinical data
This retrospective observational cost analysis was performed 
on patients enrolled in the clinical trial approved by our 
institutional review board (Policlinico Umberto I Ethics Com-
mittee) and registered on clinicaltrial.gov (NCT01820026).18 
This trial considered patients with cirrhosis with a diagnosis 
of a HCA infection consecutively admitted to the referral 
center for advanced liver diseases, from September 2012 to 
February 2016. The diagnosis of cirrhosis was based on a 
liver biopsy, when available, and/or on clinical, biochemi-
cal, ultrasonography, and endoscopic features, and exclusion 
criteria were age <18 years; advanced neoplasia, including 
hepatocellular carcinoma outside of the Milan criteria (pres-
ence of a single HCC nodule with maximum size of 5 cm, 
or as many as three nodules with the largest not exceeding 
3 cm and no macrovascular invasion); a concomitant cause 
of immunosuppression; or refusal to participate.
After obtaining written informed consent, patients were 
randomly assigned to one of two different empirical antibiotic 
treatments: standard group (mainly based on third-generation 
cephalosporins, depending on the site of infection) and broad-
spectrum group (based on imipenem–cilastatin, alone or in 
combination with other antibiotics, depending on the site of 
infection).18
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Patients selection
The present cost analysis was performed on 84 (42 for each 
group) out of 96 patients randomized in the clinical trial 
(NCT01820026) to obtain two comparable cohorts (ie, infec-
tious sites, number of episodes). Table 1 reports the main 
characteristics (demographical, clinical, biochemical, and 
infective) of the two groups.
Definitions
Infections
Spontaneous bacterial peritonitis was defined as a polymor-
phonuclear cell count greater than 250/mm3 in the ascitic fluid 
± a positive culture; pneumonia was defined as the presence 
of radiologic evidence of consolidation plus at least two of 
the following criteria: fever higher than 38°C or hypother-
mia less than 35°C; dyspnea; cough and purulent sputum; 
pleuritic chest pain; or signs of consolidation on physical 
examination. Urinary tract infections were diagnosed in pres-
ence of leucocyturia and positive culture without including 
asymptomatic bacteriuria. The evidence of a positive blood 
culture without a recognized site of infection was defined as 
spontaneous bacteremia.
Comorbidities
A diagnosis of diabetes mellitus type 2 was done in case 
of one of the following: 1) fasting plasma glucose level of 
126 mg/dL or higher, or 2) a 2-hour plasma glucose level of 
200 mg/dL or higher during a 75-g oral glucose tolerance 
test, or 3) a random plasma glucose of 200 mg/dL or higher 
in a patient with classic symptoms of hyperglycemia or 
hyperglycemic crisis.
The diagnostic criteria for organic chronic renal failure 
were the presence of either kidney damage or a decreased 
glomerular filtration rate of less than 60 mL/min/1.73 m2 for 
at least 3 months.
Cost analysis
To perform the cost analysis, the following data were col-
lected from the clinical trial medical records: antibiotic daily 
dose (number of vials), days of treatment, length of hospital 
stay, and DRG (diagnosis-related group).
The cost of antibiotics treatment was calculated multi-
plying the cost of vials by the related number of vials and 
days of treatment. The total cost of antibiotic therapy for 
each patient was the sum of costs calculated for all antibiot-
ics received during the hospitalization period. The price of 
antibiotics was based on official ex-factory prices per vial 
in Umberto I Hospital.
The profitability of hospitalizations was calculated 
 considering the related DRG tariffs. In particular, for each 
group, the total amount (DRG tariff) reimbursed for the 
hospitalizations was divided by the length of hospital stay 
(days of  hospitalization) reported in medical records. The 
DRGs considered in the present analysis were DRG202 
Table 1 Demographic, clinical, and infectious characteristics of patients treated with standard vs broad-spectrum therapy
Main characteristics Standard group Broad-spectrum group p-value
(n=42) (n=42)
Age (years), mean (range) 57.5 (53–60) 58 (53–65) n.s.
Male, n (%) 31 (74) 31 (74) n.s.
Diabetes mellitus, n (%) 16 (38) 14 (33) n.s.
Organic renal failure, n (%) 5 (12) 3 (7) n.s.
Active alcohol abuse, n (%)
(>3 alcohol units/day for man; >2 alcohol units/day for woman)
8 (19) 9 (21) n.s.
Child–Pugh score, mean ± SD 8.8+1.6 8.3+1.4 n.s.
MELD score, mean ± SD 16.6+5.5 15.3+4.6 n.s.
Hepatocellular carcinoma, n (%) 16 (33) 10 (22) n.s.
Urinary tract infections, n 22 21 n.s.
Pneumonia, n 9 9 n.s.
Spontaneous bacteremia, n 1 1 n.s.
Spontaneous bacterial peritonitis, n 10 11 n.s.
Sepsis, n (%) 22 (53) 19 (44) n.s.
C-reactive protein (mg/dL), mean (range) 2.1 (1.6–2.9) 1.9 (1.4–3) n.s.
Positive cultures, n (%) 27 (64) 28 (67) n.s.
Gram negative, n (%) 19 (70) 18 (64) n.s.
Gram positive, n (%) 8 (30) 10 (36)
Multidrug resistant, n (%) 11 (41) 12 (43) n.s.
Abbreviations: n.s., not statistically significant; MELD, Model for End-Stage Liver Disease; SD, standard deviation.
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“Liver cirrhosis and alcoholic hepatitis” and DRG203 
“Malignant hepatobiliary or pancreatic neoplasia,” as indi-
cated in medical records. For a hospital stay within 27 days, 
the reimbursement for DRG202 was €4,013, and when the 
threshold was passed an additional cost per day of €185 was 
added to the tariff. The tariff reimbursed for DRG203 was 
€4,085, considering a length of hospital stay of 35 days, 
and the additional cost per day over the threshold was €173.
Statistical analysis
Continuous data are expressed as means ± standard devia-
tions or medians with ranges according to the distribution 
of the variables. Categorical data are expressed as numbers 
and percentages. The significance of the differences between 
groups was evaluated by the Kruskal–Wallis test or χ2 test. 
All tests were two-tailed. A p-value<0.05 was considered 
statistically significant. The statistical analysis was made 
using the statistical software NCSS.
Results
Eighty-four patients were considered. The mean age of the 
patients was 57.7±12.6 years; the majority (74%) were males. 
The main origin of liver disease was hepatitis C in 49%, 
hepatitis B in 7%, and alcohol abuse in 28%. The majority of 
patients had decompensated liver disease (82% Child–Pugh 
B-C) and a Model for End-Stage Liver Disease median score 
of 15.7 (range, 6–31). Twenty-six patients had a diagnosis of 
HCC that met the Milan criteria.
As shown in Table 1, the patients included in the two 
randomized groups had similar demographic, clinical, bio-
chemical, and infectious characteristics.
Primary endpoint: costs evaluation of 
antibiotic treatments
Table 2 shows the results of the cost comparison between 
standard and broad-spectrum treatment groups. The results 
are reported as mean cost per patient treated and total cost per 
group, separately for first line of treatment (randomization), 
second line of treatment (subsequent treatment in case of 
failure), and total antibiotic treatment. As shown in Table 2, 
the standard therapy allowed to obtain a first-line treatment 
cost lower than in the broad-spectrum therapy; however, 
the latter, being related to a lower rate of treatment failure 
(19.0% vs 57.1%), resulted in cost saving by considering also 
the costs of second-line treatments. The mean cost saving per 
patient for the broad-spectrum arm was €44.18 (–37.6%), 
with a total cost saving (42 patients) of about €2,000.
Secondary endpoint: profitability of 
hospital admissions
Compared to standard group, we observed a statistically 
significant reduction in hospital stay from 17.8 to 11.8 days 
(p<0.002) for patients treated with broad-spectrum antibiot-
ics. The distribution of DRG tariffs was similar in the two 
groups (standard therapy: DRG202 69.0% DRG203 31.0%; 
broad-spectrum therapy: DRG202 71.0% DRG203 29.0%). 
Table 2 shows the profitability of hospital admissions (mean 
profitable daily cost) for standard and broad-spectrum groups. 
According to the DRG tariffs considered, the shorter length 
of hospital stay associated with the broad-spectrum group 
involved a higher mean profitable daily cost in comparison 
to the standard group (€345.61 vs €252.23; +37.0%).
Discussion
The identification of an adequate empirical antibiotic treat-
ment for bacterial infections in cirrhosis is important because 
of the high mortality related to this complication. This prob-
lem is particularly relevant in the setting of HCA infections 
because of their high rate of MDR given the usual practice 
to treat them similarly to CA.10,11,16,19
The lack of a prompt and adequate empirical treatment 
significantly increases mortality, need of further treatments, 
Table 2 Costs, length of hospitalization, and profitability of first- and second-line standard vs broad-spectrum antibiotic treatments
Variables Line of treatment Standard (A) Broad-spectrum (B) Difference B–A
Mean cost per 
patient
First line €8.78 €85.00 €76.22
Second line €152.81 €32.43 –€120.39
Total €161.59 €117.43 –€44.17
Overall costs First line €368.72 €3,570.00 €3,201.28
Second line €6,418.20 €1,361.90 –€5,056.30
Total €6,786.90 €4,931.90 –€1,855.00
Total days of hospitalization 746 495 –251
Total amount of DRG tariffs €188.20 €171.10 –€17.1 
Mean length of hospital stay (days) 17.8 11.8 –6
Mean profitable daily cost €252.20 €345.20 –€93
Abbreviations: DRG, diagnosis-related group.
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rate of complications, and length of hospital stay. No specific 
indications exist for antibiotic treatment of HCA bacterial 
infections in cirrhotic patients.
A clinical trial was performed to compare standard 
antibiotic therapy with broad-spectrum empirical antibiotic 
therapy in cirrhotic patients with HCA infections. The 
broad-spectrum approach significantly reduced in-hospital 
mortality vs standard therapy (12% vs 31%; p<0.01). The 
improvement in survival was the result of the lower thera-
peutic failure (broad spectrum 19%; standard 57%), with 
infection resolution for all infectious sites. The need of a 
second-line treatment and the length of hospital stay were 
lower in the broad-spectrum group. As a consequence of 
the above reported clinical results, we performed a cost 
analysis focused on antibiotic treatment (broad-spectrum 
therapy vs standard therapy) and hospitalization costs 
(DRG tariffs).
The cost savings per each patient treated with the broad-
spectrum therapy, compared with the standard therapy, were 
attributable to the lower failure (second-line treatment), 
which represents the main driver in the reduction of treatment 
costs. The mean cost per patient treated was €117.43 with 
broad-spectrum therapy and €161.59 with standard therapy. 
The total cost to treat all patients in broad-spectrum group 
(n=42) was 4,931.90, and it was 6,786.92 to treat all patients 
in standard group (n=42). Although standard therapy led to 
treatment costs lower than the broad-spectrum one in terms 
of first-line treatment, the latter, being related to a lower rate 
of treatment failure, was cost saving, considering the treat-
ment costs of second-line treatments. The broad-spectrum 
therapy cost saving for total antibiotic treatment (first and 
second line) was 37.6%.
The profitability of hospital admissions, calculated on 
DRG tariffs, for patient treated with broad spectrum was 
higher than standard therapy (€345.61 vs €252.23). The lower 
length of hospital stay of broad-spectrum therapy (11.8 days 
vs 17.8 days) determined a 37% higher “hospital admissions 
daily-profitability” compared with standard group.
Unfortunately, since similar analyses are currently not 
available in the medical literature, and so it is not possible 
to compare the results obtained in this cost analysis with the 
results from other studies.
A possible limitation in the current analysis could be 
attributed to the use of DRG tariffs as a “proxy” for the hospi-
talization costs. However, data obtained through DRG tariffs 
represents a valid source for carrying out a cost analysis on 
the profitability of hospital admissions. Another limitation is 
that the present results cannot be fully generalized, since the 
clinical trial we referred to was monocentric and conducted 
in a country with a high prevalence of MDR bacteria.
Conclusion
This study supports the idea that the use of a broad-spectrum 
empirical treatment for HCA infections in cirrhosis would be 
cost-saving and that hospitals need to be aware of the clinical 
and economic consequences of a wrong antibiotic treatment 
of these diseases.
Disclosure
The authors report no conflicts of interest in this work.
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